Catalyst Pharmaceuticals Inc Asset Resilience Ratio
Catalyst Pharmaceuticals Inc asset resilience ratio. Catalyst Pharmaceuticals Inc (CPRX) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Catalyst Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Catalyst Pharmaceuticals Inc (2011–2022)
Asset resilience ratio of Catalyst Pharmaceuticals Inc from 2011 to 2022. This chart shows how Catalyst Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Catalyst Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Catalyst Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CPRX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Catalyst Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Catalyst Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Catalyst Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Catalyst Pharmaceuticals Inc Asset Resilience Ratio by Year (2011–2022)
Catalyst Pharmaceuticals Inc asset resilience ratio by year from 2011 to 2022. The table below shows the annual Asset Resilience Ratio data for Catalyst Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.00% | $0.00 | $375.63 Million | -- |
| 2021-12-31 | 8.34% | $19.82 Million | $237.79 Million | +3.12pp |
| 2020-12-31 | 5.22% | $10.04 Million | $192.35 Million | +0.76pp |
| 2019-12-31 | 4.46% | $5.01 Million | $112.38 Million | -56.62pp |
| 2018-12-31 | 61.08% | $36.92 Million | $60.45 Million | +30.02pp |
| 2017-12-31 | 31.05% | $26.52 Million | $85.39 Million | -32.51pp |
| 2016-12-31 | 63.57% | $26.51 Million | $41.71 Million | +13.39pp |
| 2015-12-31 | 50.18% | $30.16 Million | $60.10 Million | -18.55pp |
| 2014-12-31 | 68.73% | $30.18 Million | $43.91 Million | -16.00pp |
| 2013-12-31 | 84.73% | $21.49 Million | $25.37 Million | +1.30pp |
| 2012-12-31 | 83.43% | $14.01 Million | $16.79 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $6.25 Million | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more